This study aims to identify useful biomarkers of early renal dysfunction among human immunodeficiency virus-infected men who have sex with men exposed to tenofovir.
Introduction
The prevalence of HIV-associated kidney disease has decreased in the era of antiretroviral therapy (ART), but drug-induced nephrotoxicity is emerging. 1 Long-term exposure to nephrotoxic antiretroviral drugs, such as tenofovir disoproxil fumarate (TDF), may lead to progression of renal dysfunction and incomplete reversibility of toxicity, even after drug withdrawal. 2, 3 Moreover, some urinary biomarkers of early kidney injury were found to be associated with important clinical outcomes, such as mortality and severe heart disease. 4, 5 Therefore, it is important to detect early renal dysfunction in HIV-infected individuals, particularly in those exposed to TDF.
TDF is widely used as a preferential drug for ART according to worldwide guidelines, and it is also part of the only approved regimen for pre-exposure prophylaxis to HIV infection. 6 The drug is excreted through glomerular filtration and proximal tubular secretion, and its use has been related to an increased risk of rapid decline in renal function and chronic kidney disease. 2 Clinically, renal insufficiency is usually assessed by an estimated glomerular filtration rate (eGFR), 7 but proximal tubular dysfunction is more common and specific for TDF-induced toxicity 8 and can occur with the absence of glomerular defects. 9 The evaluation of urinary biomarkers, such as ␣1-microglobulin (␣1M), ␤2-microglobulin (␤2M) and N-acetyl-␤-d-glucosaminidase (NAG), may improve the identification of those at risk of tubular toxicity and may detect early stages of renal dysfunction. 10, 11 However, the evaluation criteria of these proteins in tubular dysfunction have not been established and little is known about the change of these new biomarkers during ART. The role of the aforementioned biomarkers in diagnosing and monitoring early tubular damage still needs to be explored.
HIV transmission is increasing markedly faster among MSM than other high-risk groups in China and some other countries. 12, 13 MSM are at risk of TDF toxicity due to its comprehensive role in treatment and pre-exposure prophylaxis. However, most biomarkers of early renal dysfunction have not been validated in HIV-infected patients let alone in specific key-populations, such as MSM. Our study aims to investigate the presence of early renal dysfunction among HIV-infected MSM and to find the indicators of early renal injury in MSM with TDF exposure.
Materials and methods

Study population
We performed a cross-sectional study and a longitudinal study with a single-center cohort of HIV-infected MSM at the First Hospital of China Medical University in Shenyang, a major city in northern China that has a rapidly increasing incidence of HIV infection among MSM. 14 A total of 239 MSM receiving care at the AIDS clinic were enrolled in a cross-sectional study between August 2012 and June 2014. All participants in the study were adults (age ≥18 years) who were treatment-naïve or had received the current ART regimen for no less than six months. The patients who had used other non-ART nephrotoxic drugs in the previous two months before enrollment were excluded from the study.
The ART regimens were based on either Efavirenz (EFV) or Lopinavir/ritonavir (LPV/r). The other two ART drugs were lamivudine (3TC) plus TDF (TDF group) and 3TC plus zidovudine (AZT) (non-TDF group). Fifty-six patients in the non-ART group who started TDF/3TC/EFV were enrolled in a longitudinal study and were assessed after 3 and 6 months on ART. This study was approved by the Medical Research Ethics Committee of the First Hospital of China Medical University. Written informed consent for participation in this study was obtained from each participant.
Data collection
Demographic characteristics; medical history, such as diabetes, hypertension, and prior AIDS-defining illness; and other clinical and laboratory data of each subject were obtained from the clinical records and laboratory database. Body weight was also measured. Fasting blood and mid-stream urine specimens were collected at the routine morning consultation. Blood samples were assayed for full blood count, CD4T cell count, HIV RNA level, ␤2M, and routine biochemistry levels, including renal, liver, glucose, calcium, phosphorus, and lipid profiles.
Spot urine samples were tested for ␣1M, ␤2M, NAG, creatinine, and albumin within four hours after sample collection in the clinical laboratory of our hospital. The urinary levels of ␣1M, ␤2M and albumin were determined by a Siemens BN II nephelometer Analyzer II with the kits from Siemens. NAG was measured with a 6-methyl-2-pyridinethiol (MPT) assay (Leadman Biotechnologies Inc., Beijing), and urinary creatinine was measured by enzymatic methods using an automated multianalyzer (HITACHI 7600, To kyo, Japan). The upper reference limits given by the manufacturer were 0.3 mg/L for urinary ␤2M, 12 mg/L for urinary ␣1M, and 11.5 IU/L for NAG. All of the urinary proteins were expressed as the ratio-to-creatinine (␣1MCR, ␤2MCR, NAGCR, and ACR) to account for the variations in urine concentration among individuals.
Definition
Hypertension was self-reported or diagnosed as a systolic BP ≥140, diastolic BP ≥90 mmHg, or current treatment of hypertension with antihypertensive drugs. Diabetes was defined as a fasting blood glucose ≥7.0 mmol/L or a self-reported history of diabetes. Hypocalcemia and hypophosphatemia were defined based on the reference ranges in the local clinical laboratory as serum calcemia <2.17 mmol/L and serum phosphate <0.81 mmol/L. The eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKDEPI). 15 Albuminuria was defined as an ACR >30 mg/g. 16 Because there are no accepted criteria for the proteinuria of ␣1M, ␤2M and NAG, we used the upper quartile (UQ) values of ␣1MCR, ␤2MCR and NAGCR of all participants to define abnormality.
Statistical analysis
All analyses were performed using SPSS software, version 18.0 (SPSS, Inc., Chicago, IL, USA). Data are presented as means ± standard deviation (mean ± SD), medians with inter-quartile ranges (IQR) for continuous variables, and as proportions for categorical variables. Appropriate variables were compared by one-way ANOVA and independent-sample t tests for continuous variables; 2 test or Fisher exact test for categorical variables. We calculated Spearman rank correlation coefficients to determine the relationship between urinary proteins and serum ␤2M. Risk factors of UQ ␤2MCR and UQ ␣1MCR were identified with multivariate logistic regression analysis. We considered a p-value <0.05 to be statistically significant.
Results
Two-hundred-thirty-nine HIV-infected MSM were enrolled in the study and stratified by ART into the three groups: TDF group (n = 97), non-TDF group (n = 66), and non-ART group (n = 76). The characteristics of the participants are given in Table 1 . In the study sample, the frequency of hypertension, diabetes and hypophosphatemia were 2.9% (n = 7), 2.5% (n = 6), and 9.6% (n = 23), respectively. Although almost half of the Albuminuria was defined as ACR >30 mg/g. Other kinds of proteinuria were defined as ␤2MCR >0.68 mg/g, ␣1MCR >25.8 mg/g, and NAGCR >9.1 IU/g, respectively. ACR, urinary albumin-to-creatinine ratio; ␤2MCR, beta2-microglobulin-to-creatinine ratio; ␣1MCR, alpha1-microglobulin-to-creatinine ratio; NAGCR, N-acetyl-␤-d-glucosaminidase-to-creatinine ratio.
patients in the TDF group were treatment experienced with a non-TDF-containing regimen, the total ART time in both ART groups was similar (p > 0.05).
In the cross-sectional study, an eGFR < 90 mL/min/1.73 m 2 was seen in eight patients (3.3%) and an eGFR < 60 mL/min/ 1.73 m 2 was seen in only two patients (0.8%). Albuminuria was present in 12.1% of our participants. As shown in Fig. 1 and Table 2 , the TDF group had a higher frequency of ␣1M proteinuria (␣1MCR >25.8 mg/g) and a higher ␣1MCR value than the other two groups (all p < 0.05). A higher frequency of ␤2M proteinuria (␤2MCR >0.68 mg/g) was also observed in the TDF group compared to the non-TDF group (p = 0.024). No significant differences were found in ␤2MCR among the three groups. Statistical analysis revealed no significant differences in abnormal frequency or ratio-to-creatinine value of urinary NAG and albumin among the three groups.
␤2MCR and ␣1MCR (in urine) were both correlated with serum ␤2M ( Fig. 2A and B ␤2MCR, beta2-microglobulin-creatinine ratio; ␣1MCR, alpha1-microglobulin-creatinine ratio; NAGCR, N-acetyl-␤-D-glucosaminidase-creatinine ratio; ACR, albumin-creatinine ratio (urine). a A significant difference between the groups compared.
too low prevalence, such as diabetes (2.5%) and hypertension (2.9%), were not included in the analysis. To further study the impact of TDF on kidney function, we followed-up 56 MSM from the non-ART group who started TDF/3TC/EFV. As shown in Table 5 , ␣1MCR was the only urinary biomarker that dramatically increased after three and six months on TDF-containing therapy compared to baseline data (p = 0.023 and 0.011, respectively). There was a slight increasing trend of ␤2MCR (in the urine) at three months, but it disappeared at six months (all p > 0.05), concurrent with a significant decrease in ␤2M after six months of ART (p = 0.028). . ␤2MCR, beta2-microglobulin-to-creatinine ratio; ␣1MCR, alpha1-microglobulin-to-creatinine ratio.
Discussion
In an era in which early ART and pre-exposure prophylaxis are generally encouraged, 17 TDF use and its nephrotoxicity are likely to draw increasing attention. 18 In HIV-infected females, some urinary biomarkers were related to TDF use and could forecast declining kidney function. 19, 20 Among HIV-infected MSM, we observed a higher rate of ␣1M and ␤2M proteinuria in TDF users in a cross-sectional study and confirmed urinary ␣1M elevation after TDF exposure in a longitudinal study. HIV-seronegative MSM were found to have a small but significant decrease in creatinine clearance after TDF exposure, 21 but novel urinary biomarkers among this population have not been evaluated. Our findings underscored the importance of subclinical renal function monitoring in HIV-infected MSM treated with TDF, and the findings might also give clues for early detection of TDF-related toxicity in non-infected MSM.
Here we chose four urinary candidate markers to indicate early renal dysfunction: albuminuria is a classical indicator of early glomerular injury; 22 ␣1M, ␤2M, and NAG are tubular biomarkers, but their role in diagnosing and monitoring early tubular damage is still undetermined. Of all of the selected markers, urinary ␣1M seems to be the most reliable for determining TDF-associated renal dysfunction in several ways. First, urinary ␣1M was the only biomarker that could distinguish the TDF group from the other two control groups in the cross-sectional study. Second, ␣1M was also the only marker with notable elevation after ART initiation assessed in the longitudinal study. In a review paper, TDF-related renal damage usually appears within 5-12 months after initiation of therapy. 23 Our observation confirmed the sensitivity of urinary ␣1M, which increased significantly already after three months of TDF-containing therapy. Third, we observed no significant differences in albumin or NAG in cross-sectional or longitudinal studies. Urinary ␤2M might also be a helpful biomarker, which has been recommended along with urinary ␣1M as a useful screening tool for TDF-induced kidney tubulopathy in a diagnostic accuracy study, 10 and showed a higher rate of proteinuria in the TDF group than the non-TDF group in our study. However, urinary ␤2M is highly dependent on serum ␤2M and the pH value of the urine. 24, 25 Unlike ␤2M, which is unstable in acidic urine, ␣1M has been reported to be very stable in urine at different pHs. 26 It is worth mentioning that the inflammatory status of HIV infection may disturb the interpretation of urinary biomarkers in tubular dysfunction because ␣1M and ␤2M are both inflammatory biomarkers. 26, 27 In our observation, urinary ␣1MCR and ␤2MCR were both correlated to serum ␤2M, which is a non-specific marker of chronic inflammation and could be increased even after ART. 27, 28 However, serum ␤2M seemed to have a stronger effect on urinary ␤2MCR than urinary ␣1MCR. In multivariate analyses, TDF exposure was an independent risk factor for UQ ␣1MCR before and after serum ␤2M adjustment. By contrast, after adjusting for serum ␤2M, all traditional risk factors of tubular proteinuria 29 lost their significance in association with UQ ␤2MCR. In the longitudinal study, we also observed elevated ␣1MCR levels after three and six months on TDF exposure, but no obvious change was found in ␤2MCR after ART, probably due to the decreased level of serum ␤2M. Nevertheless, in another study with a longer observation time after TDF than in our study, urinary ␤2M was highly elevated. 19 It reminds us that urinary ␤2M may still be a useful marker after long-term TDF exposure and encourages further study.
Our study provided information about the presence of early renal dysfunction in Chinese HIV-infected patients. Compared with another HIV-infected cohort of African Americans and Caucasians in America, our patients had a lower rate of albuminuria (12.1% versus 28%). A recent study in Germany reported a higher rate of albuminuria (20%), but a lower rate of tubular proteinuria (41%) than that seen in our study (54.4%), as measured by their definition (␣1MCR >14 mg/g). 30 More studies using similar biomarkers and criteria of early renal dysfunction are needed. Additionally, because TDF only became a first-line drug to treat naive patients in China in 2012, future studies are required to determine its long-term toxicity in Chinese patients.
Conclusion
Urinary ␣1M seems to be a promising biomarker for early detection of TDF-associated tubular dysfunction among HIVinfected MSM. Urinary ␤2M may help indicate tubular dysfunction, but its clinical interpretation should also take inflammatory conditions into account. More studies will be necessary to address the clinical role of these biomarkers in diagnosing and monitoring TDF-associated tubular injury.
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